FDA grants breakthrough therapy designation to R-DXd for platinum-resistant ovarian and related cancers
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo